Get the Daily Brief
Latest Biotech News
SDR‑seq decodes noncoding DNA and RNA from the same cell
EMBL researchers unveiled SDR‑seq, a single‑cell sequencing method that captures both DNA and RNA from the same cell to expose functional non‑coding variants that influence gene regulation....
Rutgers maps molecular route to AML therapy resistance
Researchers from Rutgers and international collaborators identified a molecular mechanism that underlies therapy resistance in acute myeloid leukemia (AML), offering new targets to overcome...
AstraZeneca ADC push: Enhertu moves earlier; AZD5335 posts activity
AstraZeneca presented clinical data showing its antibody-drug conjugate (ADC) franchise is advancing beyond late-stage disease. At ESMO, investigators reported Enhertu produced meaningful benefit...
Tubulis’ platform vindicated — 59% response riles investors
Tubulis reported first‑in‑human data for its NaPi2b‑targeting ADC, TUB‑040, showing a confirmed overall response rate of 59% across multiple dose cohorts in heavily pretreated patients. The...
TNBC ADC showdown: Datroway versus Trodelvy — clinicians to choose
Two late‑stage ADCs targeting metastatic triple‑negative breast cancer (TNBC) produced compelling Phase 3 data presented back‑to‑back at ESMO. AstraZeneca/Daiichi Sankyo’s Datroway and Gilead’s...
Grail’s Galleri: improved specificity as FDA filing approaches
Grail released new PATHFINDER study results showing improved positive predictive value for its multi‑cancer Galleri blood test, findings that company executives argue strengthen its case for...
FDA pilot: first nine CNPV picks aim to speed review — winners named
The U.S. Food and Drug Administration revealed the first nine recipients of its Commissioner’s National Priority Voucher (CNPV) pilot program, a fast‑track mechanism intended to deliver regulatory...
mRNA COVID vaccines boost checkpoint immunotherapy — ESMO findings
Data presented at ESMO and at MD Anderson indicate that patients who received an mRNA COVID‑19 vaccine within 100 days prior to starting immune checkpoint inhibitors had longer survival than those...
Microbes and mechanics: bacteria and cell 'craters' reshape tumor resistance story
MD Anderson researchers reported that tumor‑infiltrating bacteria, notably Fusobacterium nucleatum, can induce quiescence in cancer epithelial cells, enabling immune evasion and chemotherapy...
Digital twins and consumer AI: Sophia Genetics and Verily roll out new tools
Sophia Genetics launched Sophia DDM Digital Twins, an AI‑driven research module that creates computational patient replicas using multimodal clinical, imaging and genomic data to simulate...
Partnerships and access: Rani pairs with Chugai; Orsini expands rare‑disease affordability
Rani Therapeutics entered an agreement with Chugai to pair Rani’s oral biologic delivery capsule with a Chugai experimental rare‑disease antibody in a deal valued up to $1.08 billion, signalling...
Roche’s SERD moment: giredestrant proves in non‑mutant breast cancer
Roche presented Phase 3 data indicating its selective estrogen receptor degrader (SERD) giredestrant delays tumor progression in hormone receptor‑positive breast cancer, including patients without...
ADCs collide at ESMO: AstraZeneca, Gilead reveal competing TNBC data
AstraZeneca and Gilead presented rival antibody-drug conjugate (ADC) data at the European Society for Medical Oncology (ESMO), offering the first new first-line options in years for metastatic...
Enhertu presses earlier... AstraZeneca eyes curative gains in breast cancer
AstraZeneca and Daiichi Sankyo detailed Phase 3 data showing Enhertu (trastuzumab deruxtecan) can improve outcomes when moved into earlier breast‑cancer settings, with trial leaders framing the...
Roche’s SERD proves broad activity: giredestrant shows efficacy in non‑mutant patients
Roche presented detailed Phase 3 results for its oral selective estrogen receptor degrader (SERD), giredestrant, reporting significant progression‑free survival (PFS) gains in both ESR1‑mutant and...
Grail tightens Galleri’s performance: PATHFINDER 2 shows better real‑world accuracy
Grail released updated PATHFINDER 2 data showing improved positive predictive value (PPV) and sensitivity for its multi‑cancer blood test, Galleri, strengthening the company’s case ahead of...
FDA picks nine winners for new priority review voucher pilot
The U.S. Food and Drug Administration named the first nine recipients of its Commissioner’s National Priority Review Voucher (CNPV) pilot, a program that can compress review timelines to as little...
Sophia Genetics launches Digital Twins: AI models to simulate cancer trajectories
Sophia Genetics rolled out Sophia DDM Digital Twins, an AI‑powered module designed to create computational replicas of individual cancer patients by integrating genomic, imaging, pathology and...
Tubulis validates platform: TUB‑040 posts 59% ORR amid large fundraising
Tubulis reported first‑in‑human data for its next‑generation ADC TUB‑040 showing a 59% overall response rate (ORR) across dose cohorts, validating the company’s Tubutecan payload and P5...
Tumor microbes and immune 'craters' explain pockets of resistance
Two mechanistic studies revealed how microenvironmental features blunt cancer therapy: MD Anderson researchers showed tumor‑infiltrating Fusobacterium nucleatum drives reversible cancer cell...